ESR1 and breast cancer: Guerrero-Zotano et al. identified 18 of the 20 E2F4 target genes, and suggested a potential benefit of adjuvant CDK4/6 inhibitors in patients with ER+ breast cancer who failed to respond to preoperative estrogen deprivation (49).